Merck, advancing single-dose and oral coronavirus vaccines, could still make Warp Speed: Bloomberg

merck
Merck entered early human testing for a COVID-19 vaccine candidate this month. (Merck)

The U.S. government’s Operation Warp Speed has already inked COVID-19 vaccine research and manufacturing pacts with major vaccine players—excluding Merck & Co., that is. But the group’s description of an as-yet-unnamed participant matches Merck’s early-stage research, Bloomberg reports, indicating the drugmaker could still get in.  

Merck publicly entered COVID-19 vaccine research later than its peers through a buyout of the biotech Themis and a partnership with nonprofit research group IAVI. The company started phase 1/2 testing earlier this month with technology acquired in the Themis buy. The IAVI partnership uses the same platform as Merck's Ebola vaccine, which won FDA approval late last year.

Merck’s vaccines are live attenuated candidates, meaning they use weakened viruses that replicate in the body to generate an immune response. Merck is testing a vaccine that could be given orally, which would “help lower the barrier to vaccination should it be effective,” Merck R&D chief Roger Perlmutter said on a July conference call. 

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

“In dealing with an aggressive, globally dispersed disease like COVID-19, we believe that it is wise to lower the barrier to vaccination as much as possible, for example, by launching a vaccine that is effective with just a single administration,” Perlmutter said. 

Those details match the description of a vaccine that Moncef Slaoui, head of Operation Warp Speed, highlighted as a potential participant during a Wednesday presentation, according to Bloomberg. Merck and the Department of Health and Human Services declined to comment to the news service. 

RELATED: Merck, via its Themis buy, to move first COVID-19 vaccine into clinical development in Q3 

Back in June, the New York Times reported that Merck was among a group of companies selected as Warp Speed finalists. The drugmaker has yet to enter a public deal with the group.

To help support early research, Merck struck a $38 million deal with the U.S. government’s Biomedical Advanced Research and Development Authority in May.

Operation Warp Speed agreements have been on a much larger scale than that, though, with each coming in at $1 billion or more. Warp Speed already has deals with Moderna, AstraZeneca, Novavax, Johnson & Johnson, Sanofi/GSK and Pfizer/BioNTech, which are using various vaccine technologies.

RELATED: Trailing Big Pharma peers, Merck inks deals to advance COVID-19 drugs, vaccines 

Meanwhile, leading companies are already in phase 3 testing and could secure emergency use authorizations in late 2020 or early 2021. Most of the late-stage candidates are two-dose regimens, but Johnson & Johnson just entered phase 3 with a one-dose vaccine. Pfizer has said it expects early efficacy data in late October for its two-dose regimen.

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.